Home › Encyclopedia › Ibutamoren: Uses, Research Status, and Trial Data
Approved

Ibutamoren: Uses, Research Status, and Trial Data

Molecular formulaC27H36N4O5S
Molecular weight528.7 g/mol
Registered trials8
PubChem CID178024

What ibutamoren is

Ibutamoren is a synthetic compound identified by PubChem CID 178024, with a molecular formula of C27H36N4O5S. It does not have an FDA-approved drug label, and no brand name, indication, or mechanism has been officially established through that process. Any use of ibutamoren outside of registered clinical trials falls outside FDA-approved medical practice.

Trial footprint

Ibutamoren has been registered in 8 clinical trials. Among the studies on record, one Phase 2 trial evaluated the compound for fibromyalgia and was completed, while a separate Phase 2 trial looking at sarcopenia in patients recovering from hip fracture was terminated. A related Phase 3 trial, listed under LUM-201, is currently recruiting participants with growth hormone deficiency. These records reflect trial registration and status only, not proof of safety or effectiveness for any use.

FAQ

Is ibutamoren FDA-approved?
No. Ibutamoren does not have an FDA-approved label, brand name, or approved indication. It has been studied in a limited number of registered clinical trials, but that does not mean it has been approved for any medical use.
What has ibutamoren been studied for?
Registered trials have examined ibutamoren in contexts such as fibromyalgia and sarcopenia following hip fracture, and it appears in a Phase 3 trial (as LUM-201) for growth hormone deficiency in children. Trial registration reflects that research has occurred, not that the compound is proven effective or approved.
How many clinical trials involve ibutamoren?
Public trial registries list 8 clinical trials involving ibutamoren. These trials vary in phase and status, including completed, terminated, and currently recruiting studies.
Is ibutamoren the same as a growth hormone drug?
One trial title refers to it as an oral growth hormone drug in a fibromyalgia study, but no FDA-approved label confirms this classification. Without an approved label, its official drug class has not been established.
Are there known side effects of ibutamoren?
No FDA Adverse Event Reporting System data was available for this compound at the time of this review. Because it lacks an approved label, there is no official side effect profile to reference.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov

Updated 2026-09-19